Cover Image
市場調查報告書

葡萄糖依賴性胰島素分泌性受體(G蛋白質結合受體119/GPR119):開發平台分析

Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 358348
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
葡萄糖依賴性胰島素分泌性受體(G蛋白質結合受體119/GPR119):開發平台分析 Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H1 2016
出版日期: 2016年04月27日 內容資訊: 英文 65 Pages
簡介

以GPR119知名的G蛋白質結合受體119是藉由GPR119基因編碼化的G蛋白質結合受體。胰臟與消化道可發現含有高濃度GPR119。GPR119可調節腸促胰島素和胰島素·荷爾蒙的分泌。藉由GPR119受體的活性化便可降低食物攝取,抑制體重增加。這個標的,是治療肥胖和糖尿病潛在的藥物標的。

本報告提供全球各國葡萄糖依賴性胰島素分泌性受體的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

開發中的產品的一覽(各企業)

研究中的產品的一覽(大學/研究機關別)

治療藥的評估

  • 單劑/併用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Amgen Inc.
  • Array BioPharma Inc.
  • Astellas Pharma Inc.
  • CymaBay Therapeutics, Inc.
  • 第一三共
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Hyundai Pharmaceutical Co., Ltd.
  • LG Life Science LTD.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Rhizen Pharmaceuticals S.A.
  • 三和化學研究所
  • 武田藥品工業
  • Yuhan Corporation

藥物簡介

  • 17-i
  • ARRY-981
  • AS-1669058
  • DA-1241
  • DS-8500
  • GSK-2041706
  • HD-0471042
  • HD-0471953
  • HOB-047
  • KR-69318
  • LC-34AD3
  • MBX-2982
  • Small Molecule to Agonize GPR-119 for Type 2 Diabetes
  • Small Molecule to Agonize GPR119 for Type 2 Diabetes
  • Small Molecule to Agonize GPR119 for Type II Diabetes
  • Small Molecule to Agonize GPR119 for Undisclosed Indication
  • Small Molecule to Agonize GPR119 Receptor for Undisclosed Indication
  • Small Molecules to Agonize GPR119 for Metabolic Disorders
  • Small Molecules to Agonize GPR119 for Type 2 Diabetes
  • Small Molecules to Agonize GPR119 for Type II Diabetes
  • Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes
  • YH-18420

暫停中的計劃

開發中止的產品

  • 主要消息·新聞稿

附錄

圖表

目錄
Product Code: GMDHC0001TDB

Summary

Global Markets Direct's, 'Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H1 2016', provides in depth analysis on Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) targeted pipeline therapeutics.

The report provides comprehensive information on the Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119)
  • The report reviews Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) Overview
  • Therapeutics Development
    • Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Products under Development by Stage of Development
    • Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Products under Development by Therapy Area
    • Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Products under Development by Indication
  • Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Products under Development by Companies
  • Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Products under Development by Universities/Institutes
  • Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Array BioPharma Inc.
    • Astellas Pharma Inc.
    • CymaBay Therapeutics, Inc.
    • Daiichi Sankyo Company, Limited
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Hyundai Pharmaceutical Co., Ltd.
    • LG Life Science LTD.
    • Merck & Co., Inc.
    • Neurocrine Biosciences, Inc.
    • Novartis AG
    • Rhizen Pharmaceuticals S.A.
    • Sanwa Kagaku Kenkyusho Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • Yuhan Corporation
  • Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Drug Profiles
    • 17-i - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARRY-981 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AS-1669058 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DA-1241 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-8500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2041706 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HD-0471042 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HD-0471953 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KR-69318 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LC-34AD3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MBX-2982 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GPR-119 for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GPR119 for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GPR119 for Type II Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GPR119 for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GPR119 Receptor for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GPR119 for Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GPR119 for Type II Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YH-18420 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Dormant Projects
  • Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Discontinued Products
  • Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Featured News & Press Releases
    • Nov 05, 2009: Metabolex Closes $8.6 Million Financing Round
    • Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982
    • Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Amgen Inc., H1 2016
  • Pipeline by Array BioPharma Inc., H1 2016
  • Pipeline by Astellas Pharma Inc., H1 2016
  • Pipeline by CymaBay Therapeutics, Inc., H1 2016
  • Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016
  • Pipeline by LG Life Science LTD., H1 2016
  • Pipeline by Merck & Co., Inc., H1 2016
  • Pipeline by Neurocrine Biosciences, Inc., H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by Rhizen Pharmaceuticals S.A., H1 2016
  • Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Pipeline by Yuhan Corporation, H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top